Hypoxia-inducible factor-1 and associated upstream and downstream proteins in the pathophysiology and management of glioblastoma

Neurosurgical Focus

Volumn 37, Issue 6, 2014, Pages

  Womeldorff, Matthew ^a   Gillespie, David ^a   Jensen, Randy L ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Glioblastoma; Glycolysis; Hypoxia; Hypoxia inducible factor; Metabolism

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1;

BRAIN NEOPLASMS; CHEMICAL STRUCTURE; GLIOBLASTOMA; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MODELS, MOLECULAR; SIGNAL TRANSDUCTION;

EID: 84916935120     PISSN: None     EISSN: 10920684     Source Type: Journal    
DOI: 10.3171/2014.9.FOCUS14496     Document Type: Article

References (257)

1. Abounader R, Lal B, Luddy C, Koe G, Davidson B, Rosen EM, et al: In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J 16:108-110, 2002
2. Abounader R, Ranganathan S, Lal B, Fielding K, Book A, Dietz H, et al: Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/ hepatocyte growth factor and c-met expression. J Natl Cancer Inst 91:1548-1556, 1999
3. Aghi M, Cohen KS, Klein RJ, Scadden DT, Chiocca EA: Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Res 66:9054-9064, 2006
4. Ali MA, Reis A, Ding LH, Story MD, Habib AA, Chattopadhyay A, et al: SNS-032 prevents hypoxia-mediated glioblastoma cell invasion by inhibiting hypoxia inducible factor-1alpha expression. Int J Oncol 34:1051-1060, 2009
5. Annabi B, Lee YT, Turcotte S, Naud E, Desrosiers RR, Champagne M, et al: Hypoxia promotes murine bone-marrow-derived stromal cell migration and tube formation. Stem Cells 21:337-347, 2003
6. Bae SH, Jeong JW, Park JA, Kim SH, Bae MK, Choi SJ, et al: Sumoylation increases HIF-1alpha stability and its transcriptional activity. Biochem Biophys Res Commun 324:394-400, 2004
7. Behrooz A, Ismail-Beigi F: Stimulation of glucose transport by hypoxia: signals and mechanisms. News Physiol Sci 14:105-110, 1999
8. Bergers G, Hanahan D: Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592-603, 2008
9. Bilton R, Mazure N, Trottier E, Hattab M, Déry MA, Richard DE, et al: Arrest-defective-1 protein, an acetyltransferase, does not alter stability of hypoxia-inducible factor (HIF)-1alpha and is not induced by hypoxia or HIF. J Biol Chem 280:31132-31140, 2005
10. Bloom HJ: Intracranial tumors: response and resistance to therapeutic endeavors, 1970-1980. Int J Radiat Oncol Biol Phys 8:1083-1113, 1982
11. Blouw B, Song H, Tihan T, Bosze J, Ferrara N, Gerber HP, et al: The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4:133-146, 2003
12. Blum R, Jacob-Hirsch J, Amariglio N, Rechavi G, Kloog Y: Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. Cancer Res 65:999-1006, 2005
13. Boridy S, Le PU, Petrecca K, Maysinger D: Celastrol targets proteostasis and acts synergistically with a heat-shock protein 90 inhibitor to kill human glioblastoma cells. Cell Death Dis 5:e1216, 2014
14. Brat DJ, Castellano-Sanchez AA, Hunter SB, Pecot M, Cohen C, Hammond EH, et al: Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 64:920-927, 2004
15. Brat DJ, Mapstone TB: Malignant glioma physiology: cellular response to hypoxia and its role in tumor progression. Ann Intern Med 138:659-668, 2003
16. Buchanan IM, Scott T, Tandle AT, Burgan WE, Burgess TL, Tofilon PJ, et al: Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102. J Cell Mol Med 15:1999-2006, 2011
17. Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T, et al: Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 66:1721-1729, 2006
18. Cantley LC, Neel BG: New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 96:4240-4245, 1999
19. Cao X, Fang L, Gibbs S, Huang Y, Dai Z, Wen P, et al: Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemother Pharmacol 59:495-505, 2007
20. Cao XX, Xu JD, Xu JW, Liu XL, Cheng YY, Li QQ, et al: RACK1 promotes breast carcinoma migration/metastasis via activation of the RhoA/Rho kinase pathway. Breast Cancer Res Treat 126:555-563, 2011
21. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, et al: Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394:485-490, 1998 (Erratum in Nature 395:525, 1998)
22. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, et al: Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10:858-864, 2004
23. Chakravarti A, Zhai G, Suzuki Y, Sarkesh S, Black PM, Muzikansky A, et al: The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 22:1926-1933, 2004
24. Chen F, Kishida T, Duh FM, Renbaum P, Orcutt ML, Schmidt L, et al: Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene. Cancer Res 55:4804-4807, 1995
25. Chen L, Han L, Zhang K, Shi Z, Zhang J, Zhang A, et al: VHL regulates the effects of miR-23b on glioma survival and invasion via suppression of HIF-1a/VEGF and b-catenin/Tcf-4 signaling. Neuro Oncol 14:1026-1036, 2012
26. Chen Z, Htay A, Dos Santos W, Gillies GT, Fillmore HL, Sholley MM, et al: In vitro angiogenesis by human umbilical vein endothelial cells (HUVEC) induced by three-dimensional co-culture with glioblastoma cells. J Neurooncol 92:121-128, 2009
27. Chesnelong C, Chaumeil MM, Blough MD, Al-Najjar M, Stechishin OD, Chan JA, et al: Lactate dehydrogenase A silencing in IDH mutant gliomas. Neuro Oncol 16:686-695, 2014
28. Chiavarina B, Whitaker-Menezes D, Migneco G, Martinez-Outschoorn UE, Pavlides S, Howell A, et al: HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: autophagy drives compartment-specific oncogenesis. Cell Cycle 9:3534-3551, 2010
29. Cho KH, Choi MJ, Jeong KJ, Kim JJ, Hwang MH, Shin SC, et al: A ROS/STAT3/HIF-1a signaling cascade mediates EGFinduced TWIST1 expression and prostate cancer cell invasion. Prostate 74:528-536, 2014
30. Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, et al: Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63:2742-2746, 2003
31. Comito G, Calvani M, Giannoni E, Bianchini F, Calorini L, Torre E, et al: HIF-1a stabilization by mitochondrial ROS promotes Met-dependent invasive growth and vasculogenic mimicry in melanoma cells. Free Radic Biol Med 51:893-904, 2011
32. Cooper R, Sarioglu S, Sökmen S, Füzün M, Küpelioglu A, Valentine H, et al: Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma? Br J Cancer 89:870-876, 2003
33. Cuvier C, Jang A, Hill RP: Exposure to hypoxia, glucose starvation and acidosis: effect on invasive capacity of murine tumor cells and correlation with cathepsin (L + B) secretion. Clin Exp Metastasis 15:19-25, 1997
34. Davis M, Pragani R, Popovici-Muller J, Gross S, Thorne N, Salituro F, et al: ML309: a potent inhibitor of R132H mutant IDH1 capable of reducing 2-hydroxyglutarate production in U87 MG glioblastoma cells, in Probe Reports from the NIH Molecular Libraries Program. Bethesda, MD: National Center for Biotechnology Information, 2010
35. Davis MI, Gross S, Shen M, Straley KS, Pragani R, Lea WA, et al: Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1. J Biol Chem 289:13717-13725, 2014
36. De Bacco F, Casanova E, Medico E, Pellegatta S, Orzan F, Albano R, et al: The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Res 72:4537-4550, 2012
37. De Falco E, Porcelli D, Torella AR, Straino S, Iachininoto MG, Orlandi A, et al: SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. Blood 104:3472-3482, 2004
38. Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G, et al: Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 66:5549-5554, 2006
39. Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegué E, et al: HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13:206-220, 2008
40. Duan Y, Zhao X, Ren W, Wang X, Yu KF, Li D, et al: Antitumor activity of dichloroacetate on C6 glioma cell: in vitro and in vivo evaluation. Onco Targets Ther 6:189-198, 2013
41. Eckerich C, Zapf S, Fillbrandt R, Loges S, Westphal M, Lamszus K: Hypoxia can induce c-Met expression in glioma cells and enhance SF/HGF-induced cell migration. Int J Cancer 121:276-283, 2007
42. El Sayed SM, Abou El-Magd RM, Shishido Y, Chung SP, Sakai T, Watanabe H, et al: D-amino acid oxidase gene therapy sensitizes glioma cells to the antiglycolytic effect of 3-bromopyruvate. Cancer Gene Ther 19:1-18, 2012
43. El Sayed SM, El-Magd RM, Shishido Y, Chung SP, Diem TH, Sakai T, et al: 3-Bromopyruvate antagonizes effects of lactate and pyruvate, synergizes with citrate and exerts novel antiglioma effects. J Bioenerg Biomembr 44:61-79, 2012
44. El Sayed SM, El-Magd RM, Shishido Y, Yorita K, Chung SP, Tran DH, et al: D-Amino acid oxidase-induced oxidative stress, 3-bromopyruvate and citrate inhibit angiogenesis, exhibiting potent anticancer effects. J Bioenerg Biomembr 44:513-523, 2012
45. Evans A, Bates V, Troy H, Hewitt S, Holbeck S, Chung YL, et al: Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies. Cancer Chemother Pharmacol 61:377-393, 2008
46. Eyler CE, Rich JN: Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 26:2839-2845, 2008
47. Ezhilarasan R, Mohanam I, Govindarajan K, Mohanam S: Glioma cells suppress hypoxia-induced endothelial cell apoptosis and promote the angiogenic process. Int J Oncol 30:701-707, 2007
48. Fang J, Xia C, Cao Z, Zheng JZ, Reed E, Jiang BH: Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J 19:342-353, 2005
49. Flynn JR, Wang L, Gillespie DL, Stoddard GJ, Reid JK, Owens J, et al: Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme. Cancer 113:1032-1042, 2008
50. Folkins C, Shaked Y, Man S, Tang T, Lee CR, Zhu Z, et al: Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res 69:7243-7251, 2009
51. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, et al: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604-4613, 1996
52. Franovic A, Holterman CE, Payette J, Lee S: Human cancers converge at the HIF-2alpha oncogenic axis. Proc Natl Acad Sci U S A 106:21306-21311, 2009
53. Fujiwara K, Iwado E, Mills GB, Sawaya R, Kondo S, Kondo Y: Akt inhibitor shows anticancer and radiosensitizing effects in malignant glioma cells by inducing autophagy. Int J Oncol 31:753-760, 2007
54. Fujiwara S, Nakagawa K, Harada H, Nagato S, Furukawa K, Teraoka M, et al: Silencing hypoxia-inducible factor-1alpha inhibits cell migration and invasion under hypoxic environment in malignant gliomas. Int J Oncol 30:793-802, 2007
55. Fults D, Pedone CA, Thompson GE, Uchiyama CM, Gumpper KL, Iliev D, et al: Microsatellite deletion mapping on chromosome 10q and mutation analysis of MMAC1, FAS, and MXI1 in human glioblastoma multiforme. Int J Oncol 12:905-910, 1998
56. Furuta T, Nakada M, Misaki K, Sato Y, Hayashi Y, Nakanuma Y, et al: Molecular analysis of a recurrent glioblastoma treated with bevacizumab. Brain Tumor Pathol 31:32-39, 2014
57. Gadducci A, Guerrieri ME, Greco C: Tissue biomarkers as prognostic variables of cervical cancer. Crit Rev Oncol Hematol 86:104-129, 2013
58. Gaspar N, Sharp SY, Eccles SA, Gowan S, Popov S, Jones C, et al: Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma. Mol Cancer Ther 9:1219-1233, 2010
59. Gatenby RA, Kessler HB, Rosenblum JS, Coia LR, Moldofsky PJ, Hartz WH, et al: Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 14:831-838, 1988
60. Gillespie D, Arce-Larreta M, Ravichandran S, Leishman L, Berrondo C, Gamboa J, et al: RNA interference targeting HIF-1a via a novel multifunctional surfactant attenuates glioma growth in an intracranial mouse model. J Neurosurg [in press]
61. Gillespie DL, Whang K, Ragel BT, Flynn JR, Kelly DA, Jensen RL: Silencing of hypoxia inducible factor-1alpha by RNA interference attenuates human glioma cell growth in vivo. Clin Cancer Res 13:2441-2448, 2007
62. Gnarra JR, Zhou S, Merrill MJ, Wagner JR, Krumm A, Papavassiliou E, et al: Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A 93:10589-10594, 1996
63. Graham CH, Forsdike J, Fitzgerald CJ, Macdonald-Goodfellow S: Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int J Cancer 80:617-623, 1999
64. Grosso S, Doyen J, Parks SK, Bertero T, Paye A, Cardinaud B, et al: MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines. Cell Death Dis 4:e544, 2013
65. Guessous F, Zhang Y, diPierro C, Marcinkiewicz L, Sarkaria J, Schiff D, et al: An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth. Anticancer Agents Med Chem 10:28-35, 2010
66. Guo J, Shinriki S, Su Y, Nakamura T, Hayashi M, Tsuda Y, et al: Hypoxia suppresses cylindromatosis (CYLD) expression to promote inflammation in glioblastoma: possible link to acquired resistance to anti-VEGF therapy. Oncotarget 15:6353-6364, 2014
67. Haase VH: The VHL/HIF oxygen-sensing pathway and its relevance to kidney disease. Kidney Int 69:1302-1307, 2006
68. Han JY, Oh SH, Morgillo F, Myers JN, Kim E, Hong WK, et al: Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. J Natl Cancer Inst 97:1272-1286, 2005
69. Harada H: How can we overcome tumor hypoxia in radiation therapy? J Radiat Res (Tokyo) 52:545-556, 2011
70. He G, Jiang Y, Zhang B, Wu G: The effect of HIF-1a on glucose metabolism, growth and apoptosis of pancreatic cancerous cells. Asia Pac J Clin Nutr 23:174-180, 2014
71. Helbig L, Koi L, Brüchner K, Gurtner K, Hess-Stumpp H, Unterschemmann K, et al: Hypoxia-inducible factor pathway inhibition resolves tumor hypoxia and improves local tumor control after single-dose irradiation. Int J Radiat Oncol Biol Phys 88:159-166, 2014
72. Hennessey D, Martin LM, Atzberger A, Lynch TH, Hollywood D, Marignol L: Exposure to hypoxia following irradiation increases radioresistance in prostate cancer cells. Urol Oncol 31:1106-1116, 2013
73. Henze AT, Riedel J, Diem T, Wenner J, Flamme I, Pouyseggur J, et al: Prolyl hydroxylases 2 and 3 act in gliomas as protective negative feedback regulators of hypoxia-inducible factors. Cancer Res 70:357-366, 2010
74. Hewitson KS, McNeill LA, Riordan MV, Tian YM, Bullock AN, Welford RW, et al: Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem 277:26351-26355, 2002
75. Hiddingh L, Raktoe RS, Jeuken J, Hulleman E, Noske DP, Kaspers GJ, et al: Identification of temozolomide resistance factors in glioblastoma via integrative miRNA/mRNA regulatory network analysis. Sci Rep 4:5260, 2014
76. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P: Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56:4509-4515, 1996
77. Höckel M, Schlenger K, Höckel S, Aral B, Schäffer U, Vaupel P: Tumor hypoxia in pelvic recurrences of cervical cancer. Int J Cancer 79:365-369, 1998
78. Hu F, Tao Z, Wang M, Li G, Zhang Y, Zhong H, et al: RACK1 promoted the growth and migration of the cancer cells in the progression of esophageal squamous cell carcinoma. Tumour Biol 34:3893-3899, 2013
79. Hu YL, DeLay M, Jahangiri A, Molinaro AM, Rose SD, Carbonell WS, et al: Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. Cancer Res 72:1773-1783, 2012
80. Huveldt D, Lewis-Tuffin LJ, Carlson BL, Schroeder MA, Rodriguez F, Giannini C, et al: Targeting Src family kinases inhibits bevacizumab-induced glioma cell invasion. PLoS ONE 8:e56505, 2013
81. Ichimura K, Schmidt EE, Miyakawa A, Goike HM, Collins VP: Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades. Genes Chromosomes Cancer 22:9-15, 1998
82. Ihnatko R, Kubes M, Takacova M, Sedlakova O, Sedlak J, Pastorek J, et al: Extracellular acidosis elevates carbonic anhydrase IX in human glioblastoma cells via transcriptional modulation that does not depend on hypoxia. Int J Oncol 29:1025-1033, 2006
83. Ino Y, Yamazaki-Itoh R, Oguro S, Shimada K, Kosuge T, Zavada J, et al: Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer. PLoS ONE 8:e55146, 2013
84. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM: Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 277:29936-29944, 2002
85. Ivanov S, Liao SY, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, Weirich G, et al: Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158:905-919, 2001
86. Jahangiri A, De Lay M, Miller LM, Carbonell WS, Hu YL, Lu K, et al: Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res 19:1773-1783, 2013
87. Jelluma N, Yang X, Stokoe D, Evan GI, Dansen TB, Haas-Kogan DA: Glucose withdrawal induces oxidative stress followed by apoptosis in glioblastoma cells but not in normal human astrocytes. Mol Cancer Res 4:319-330, 2006
88. Jensen RL: Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol 92:317-335, 2009
89. Jensen RL: Hypoxia in the tumorigenesis of gliomas and as a potential target for therapeutic measures. Neurosurg Focus 20(4):E24, 2006
90. Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, Bae MH, et al: Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111:709-720, 2002
91. Jha MK, Suk K: Pyruvate dehydrogenase kinase as a potential therapeutic target for malignant gliomas. Brain Tumor Res Treat 1:57-63, 2013
92. Jhaveri N, Cho H, Torres S, Wang W, Schönthal AH, Petasis NA, et al: Noscapine inhibits tumor growth in TMZ-resistant gliomas. Cancer Lett 312:245-252, 2011
93. Jiang BH, Rue E, Wang GL, Roe R, Semenza GL: Dimerization, DNA binding, and transactivation properties of hypoxiainducible factor 1. J Biol Chem 271:17771-17778, 1996
94. Jin J, Bae KH, Yang H, Lee SJ, Kim H, Kim Y, et al: In vivo specific delivery of c-Met siRNA to glioblastoma using cationic solid lipid nanoparticles. Bioconjug Chem 22:2568-2572, 2011
95. Joo KM, Jin J, Kim E, Ho Kim K, Kim Y, Gu Kang B, et al: MET signaling regulates glioblastoma stem cells. Cancer Res 72:3828-3838, 2012
96. Jun HJ, Bronson RT, Charest A: Inhibition of EGFR induces a c-MET-driven stem cell population in glioblastoma. Stem Cells 32:338-348, 2014
97. Jun HT, Sun J, Rex K, Radinsky R, Kendall R, Coxon A, et al: AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res 13:6735-6742, 2007
98. Kaelin WG Jr: Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2:673-682, 2002
99. Kaluz S, Kaluzová M, Stanbridge EJ: Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1alpha C-terminal activation domain. Mol Cell Biol 26:5895-5907, 2006
100. Kaluz S, Van Meir EG: At the crossroads of cancer and inflammation: Ras rewires an HIF-driven IL-1 autocrine loop. J Mol Med (Berl) 89:91-94, 2011
101. Kanno H, Sato H, Yokoyama TA, Yoshizumi T, Yamada S: The VHL tumor suppressor protein regulates tumorigenicity of U87-derived glioma stem-like cells by inhibiting the JAK/STAT signaling pathway. Int J Oncol 42:881-886, 2013
102. Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG: Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol 7:134-153, 2005
103. Keith B, Johnson RS, Simon MC: HIF1a and HIF2a: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 12:9-22, 2012
104. Kessler J, Hahnel A, Wichmann H, Rot S, Kappler M, Bache M, et al: HIF-1a inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression. BMC Cancer 10:605, 2010
105. Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, et al: Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A 108:3749-3754, 2011
106. Kietzmann T, Krones-Herzig A, Jungermann K: Signaling cross-talk between hypoxia and glucose via hypoxia-inducible factor 1 and glucose response elements. Biochem Pharmacol 64:903-911, 2002
107. Kim KJ, Wang L, Su YC, Gillespie GY, Salhotra A, Lal B, et al: Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res 12:1292-1298, 2006
108. Kimura H, Weisz A, Kurashima Y, Hashimoto K, Ogura T, D'Acquisto F, et al: Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. Blood 95:189-197, 2000
109. Koh MY, Powis G: Passing the baton: the HIF switch. Trends Biochem Sci 37:364-372, 2012
110. Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S, et al: Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 483:484-488, 2012
111. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG Jr: Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1:237-246, 2002
112. Koul D: PTEN signaling pathways in glioblastoma. Cancer Biol Ther 7:1321-1325, 2008
113. Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH: Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 19:5435-5443, 2000
114. Kumar K, Wigfield S, Gee HE, Devlin CM, Singleton D, Li JL, et al: Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts. J Mol Med (Berl) 91:749-758, 2013
115. Kumar S, Arbab AS: Neovascularization in glioblastoma: current pitfall in anti-angiogenic therapy. Zhong Liu Za Zhi 1:16-19, 2013
116. Kwon HS, Kim DR, Yang EG, Park YK, Ahn HC, Min SJ, et al: Inhibition of VEGF transcription through blockade of the hypoxia inducible factor-1a-p300 interaction by a small molecule. Bioorg Med Chem Lett 22:5249-5252, 2012
117. Lal A, Peters H, St Croix B, Haroon ZA, Dewhirst MW, Strausberg RL, et al: Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst 93:1337-1343, 2001
118. Lal B, Xia S, Abounader R, Laterra J: Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation. Clin Cancer Res 11:4479-4486, 2005
119. LaVallee TM, Burke PA, Swartz GM, Hamel E, Agoston GE, Shah J, et al: Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198. Mol Cancer Ther 7:1472-1482, 2008
120. Lawrence RE, Salgia R: MET molecular mechanisms and therapies in lung cancer. Cell Adhes Migr 4:146-152, 2010
121. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, et al: Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A 107:2037-2042, 2010
122. Lee K, Kim HM: A novel approach to cancer therapy using PX-478 as a HIF-1a inhibitor. Arch Pharm Res 34:1583-1585, 2011
123. Leibel SA, Scott CB, Loeffler JS: Contemporary approaches to the treatment of malignant gliomas with radiation therapy. Semin Oncol 21:198-219, 1994
124. Li C, Liu Y, Liu J, Chen Y, Li Z, Chen X, et al: Rapamycin inhibits human glioma cell proliferation through down-regulating mammalian target of rapamycin pathway and up-regulating microRNA-143. Head Neck Oncol 4:66, 2012
125. Li DW, Zhou L, Jin B, Xie J, Dong P: Expression and significance of hypoxia-inducible factor-1a and survivin in laryngeal carcinoma tissue and cells. Otolaryngol Head Neck Surg 148:75-81, 2013
126. Li J, Guo Y, Feng X, Wang Z, Wang Y, Deng P, et al: Receptor for activated C kinase 1 (RACK1): a regulator for migration and invasion in oral squamous cell carcinoma cells. J Cancer Res Clin Oncol 138:563-571, 2012
127. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943-1947, 1997
128. Li Y, Li A, Glas M, Lal B, Ying M, Sang Y, et al: c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc Natl Acad Sci U S A 108:9951-9956, 2011
129. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, et al: Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15:501-513, 2009
130. Liu H, Li Y, Raisch KP: Clotrimazole induces a late G1 cell cycle arrest and sensitizes glioblastoma cells to radiation in vitro. Anticancer Drugs 21:841-849, 2010
131. Liu YV, Baek JH, Zhang H, Diez R, Cole RN, Semenza GL: RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha. Mol Cell 25:207-217, 2007
132. Lu H, Forbes RA, Verma A: Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 277:23111-23115, 2002
133. Lu J, Zhang K, Chen S, Wen W: Grape seed extract inhibits VEGF expression via reducing HIF-1alpha protein expression. Carcinogenesis 30:636-644, 2009
134. Lu KV, Bergers G: Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. CNS Oncol 2:49-65, 2013
135. Luwor RB, Stylli SS, Kaye AH: The role of Stat3 in glioblastoma multiforme. J Clin Neurosci 20:907-911, 2013
136. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, et al: 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3:363-375, 2003
137. Mabjeesh NJ, Post DE, Willard MT, Kaur B, Van Meir EG, Simons JW, et al: Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 62:2478-2482, 2002
138. Mack FA, Rathmell WK, Arsham AM, Gnarra J, Keith B, Simon MC: Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell 3:75-88, 2003
139. Madan J, Pandey RS, Jain V, Katare OP, Chandra R, Katyal A: Poly (ethylene)-glycol conjugated solid lipid nanoparticles of noscapine improve biological half-life, brain delivery and efficacy in glioblastoma cells. Nanomedicine (Lond Print) 9:492-503, 2013
140. Mahon PC, Hirota K, Semenza GL: FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15:2675-2686, 2001
141. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, et al: mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10:594-601, 2004
142. Martell RL, Slapak CA, Levy SB: Effect of glucose transport inhibitors on vincristine efflux in multidrug-resistant murine erythroleukaemia cells overexpressing the multidrug resistanceassociated protein (MRP) and two glucose transport proteins, GLUT1 and GLUT3. Br J Cancer 75:161-168, 1997
143. Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, et al: A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 12:6144-6152, 2006
144. Masui K, Cavenee WK, Mischel PS: mTORC2 dictates Warburg effect and drug resistance. Cell Cycle 13:1053-1054, 2014
145. Masui K, Tanaka K, Akhavan D, Babic I, Gini B, Matsutani T, et al: mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab 18:726-739, 2013
146. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275, 1999
147. McCarty JH: Glioblastoma resistance to anti-VEGF therapy: has the challenge been MET? Clin Cancer Res 19:1631-1633, 2013
148. McIntyre A, Patiar S, Wigfield S, Li JL, Ledaki I, Turley H, et al: Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy. Clin Cancer Res 18:3100-3111, 2012
149. Meijer TW, Kaanders JH, Span PN, Bussink J: Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res 18:5585-5594, 2012
150. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, et al: Hypoxia inhibits paclitaxel-induced apoptosis through adenosine-mediated phosphorylation of bad in glioblastoma cells. Mol Pharmacol 72:162-172, 2007
151. Michaud NR, Jani JP, Hillerman S, Tsaparikos KE, Barbacci-Tobin EG, Knauth E, et al: Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621. MAbs 4:710-723, 2012
152. Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E, et al: Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med 2:31ra34, 2010
153. Mie Lee Y, Kim SH, Kim HS, Jin Son M, Nakajima H, Jeong Kwon H, et al: Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochem Biophys Res Commun 300:241-246, 2003
154. Miekus K, Kijowski J, Sekula M, Majka M: 17AEP-GA, an HSP90 antagonist, is a potent inhibitor of glioblastoma cell proliferation, survival, migration and invasion. Oncol Rep 28:1903-1909, 2012
155. Milanovic D, Firat E, Grosu AL, Niedermann G: Increased radiosensitivity and radiothermosensitivity of human pancreatic MIA PaCa-2 and U251 glioblastoma cell lines treated with the novel Hsp90 inhibitor NVP-HSP990. Radiat Oncol 8:42, 2013
156. Mirimanoff RO: The evolution of chemoradiation for glioblastoma: a modern success story. Curr Oncol Rep 8:50-53, 2006
157. Morfouace M, Lalier L, Bahut M, Bonnamain V, Naveilhan P, Guette C, et al: Comparison of spheroids formed by rat glioma stem cells and neural stem cells reveals differences in glucose metabolism and promising therapeutic applications. J Biol Chem 287:33664-33674, 2012
158. Na YR, Han KC, Park H, Yang EG: Menadione and ethacrynic acid inhibit the hypoxia-inducible factor (HIF) pathway by disrupting HIF-1a interaction with p300. Biochem Biophys Res Commun 434:879-884, 2013
159. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, et al: Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 65:3307-3318, 2005
160. Nardinocchi L, Pantisano V, Puca R, Porru M, Aiello A, Grasselli A, et al: Zinc downregulates HIF-1a and inhibits its activity in tumor cells in vitro and in vivo. PLoS ONE 5:e15048, 2010
161. Narita T, Yin S, Gelin CF, Moreno CS, Yepes M, Nicolaou KC, et al: Identification of a novel small molecule HIF-1alpha translation inhibitor. Clin Cancer Res 15:6128-6136, 2009
162. Navis AC, Bourgonje A, Wesseling P, Wright A, Hendriks W, Verrijp K, et al: Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2. PLoS ONE 8:e58262, 2013
163. Newcomb EW, Lukyanov Y, Smirnova I, Schnee T, Zagzag D: Noscapine induces apoptosis in human glioma cells by an apoptosis-inducing factor-dependent pathway. Anticancer Drugs 19:553-563, 2008
164. Nishioka T, Oda Y, Seino Y, Yamamoto T, Inagaki N, Yano H, et al: Distribution of the glucose transporters in human brain tumors. Cancer Res 52:3972-3979, 1992
165. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H: IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15:6002-6007, 2009
166. Ohgaki H, Kleihues P: The definition of primary and secondary glioblastoma. Clin Cancer Res 19:764-772, 2013
167. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, et al: Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2:423-427, 2000
168. Olmez OF, Cubukcu E, Evrensel T, Kurt M, Avci N, Tolunay S, et al: The immunohistochemical expression of c-Met is an independent predictor of survival in patients with glioblastoma multiforme. Clin Transl Oncol 16:173-177, 2014
169. Onnis B, Rapisarda A, Melillo G: Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med 13 (9A):2780-2786, 2009
170. Osada M, Imaoka S, Funae Y: Apigenin suppresses the expression of VEGF, an important factor for angiogenesis, in endothelial cells via degradation of HIF-1alpha protein. FEBS Lett 575:59-63, 2004
171. Peng R, Jiang B, Ma J, Ma Z, Wan X, Liu H, et al: Forced downregulation of RACK1 inhibits glioma development by suppressing Src/Akt signaling activity. Oncol Rep 30:2195-2202, 2013
172. Petit I, Jin D, Rafii S: The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol 28:299-307, 2007
173. Piao Y, Liang J, Holmes L, Henry V, Sulman E, de Groot JF: Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin Cancer Res 19:4392-4403, 2013
174. Polivka J, Polivka J Jr, Rohan V, Pesta M, Repik T, Pitule P, et al: Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in West Bohemia. Biomed Res Int 2014:735659, 2014
175. Pollard PJ, Brière JJ, Alam NA, Barwell J, Barclay E, Wortham NC, et al: Accumulation of Krebs cycle intermediates and overexpression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 14:2231-2239, 2005
176. Pore N, Gupta AK, Cerniglia GJ, Maity A: HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells. Neoplasia 8:889-895, 2006
177. Porter JR, Ge J, Lee J, Normant E, West K: Ansamycin inhibitors of Hsp90: nature's prototype for anti-chaperone therapy. Curr Top Med Chem 9:1386-1418, 2009
178. Poteet E, Choudhury GR, Winters A, Li W, Ryou MG, Liu R, et al: Reversing the Warburg effect as a treatment for glioblastoma. J Biol Chem 288:9153-9164, 2013
179. Potter CP, Harris AL: Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer 89:2-7, 2003
180. Proescholdt MA, Merrill MJ, Stoerr EM, Lohmeier A, Pohl F, Brawanski A: Function of carbonic anhydrase IX in glioblastoma multiforme. Neuro Oncol 14:1357-1366, 2012
181. Qi Q, Liu X, Li S, Joshi HC, Ye K: Synergistic suppression of noscapine and conventional chemotherapeutics on human glioblastoma cell growth. Acta Pharmacol Sin 34:930-938, 2013
182. Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH, Melillo G: Topoisomerase I-mediated inhibition of hypoxiainducible factor 1: mechanism and therapeutic implications. Cancer Res 64:1475-1482, 2004
183. Rapisarda A, Zalek J, Hollingshead M, Braunschweig T, Uranchimeg B, Bonomi CA, et al: Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 64:6845-6848, 2004
184. Rastogi S, Banerjee S, Chellappan S, Simon GR: Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines. Cancer Lett 257:244-251, 2007
185. Rath P, Lal B, Ajala O, Li Y, Xia S, Kim J, et al: In vivo c-Met pathway inhibition depletes human glioma xenografts of tumorpropagating stem-like cells. Transl Oncol 6:104-111, 2013
186. Raza SM, Fuller GN, Rhee CH, Huang S, Hess K, Zhang W, et al: Identification of necrosis-associated genes in glioblastoma by cDNA microarray analysis. Clin Cancer Res 10:212-221, 2004
187. Reece KM, Richardson ED, Cook KM, Campbell TJ, Pisle ST, Holly AJ, et al: Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1a/p300 complex in a preclinical model of prostate cancer. Mol Cancer 13:91, 2014
188. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al: ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6:1-6, 2004
189. Rice GC, Hoy C, Schimke RT: Transient hypoxia enhances the frequency of dihydrofolate reductase gene amplification in Chinese hamster ovary cells. Proc Natl Acad Sci U S A 83:5978-5982, 1986
190. Richard DE, Berra E, Pouysségur J: Angiogenesis: how a tumor adapts to hypoxia. Biochem Biophys Res Commun 266:718-722, 1999
191. Robey IF, Lien AD, Welsh SJ, Baggett BK, Gillies RJ: Hypoxiainducible factor-1alpha and the glycolytic phenotype in tumors. Neoplasia 7:324-330, 2005
192. Rong Y, Durden DL, Van Meir EG, Brat DJ: 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol 65:529-539, 2006
193. Rossetto M, Ciccarino P, Boisselier B, Labussiere M, Sanson M: Metabolism of glioma and IDH1/IDH2 mutations. Rev Neurol (Paris) 167:699-703, 2011
194. Said HM, Hagemann C, Carta F, Katzer A, Polat B, Staab A, et al: Hypoxia induced CA9 inhibitory targeting by two different sulfonamide derivatives including acetazolamide in human glioblastoma. Bioorg Med Chem 21:3949-3957, 2013
195. Sami A, Karsy M: Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding. Tumour Biol 34:1991-2002, 2013
196. Sanna K, Rofstad EK: Hypoxia-induced resistance to doxorubicin and methotrexate in human melanoma cell lines in vitro. Int J Cancer 58:258-262, 1994
197. Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, et al: Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res 14:2900-2908, 2008
198. Sathornsumetee S, Cao Y, Marcello JE, Herndon JE II, McLendon RE, Desjardins A, et al: Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 26:271-278, 2008
199. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, et al: Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7:77-85, 2005
200. Seliger C, Leukel P, Moeckel S, Jachnik B, Lottaz C, Kreutz M, et al: Lactate-modulated induction of THBS-1 activates transforming growth factor (TGF)-beta2 and migration of glioma cells in vitro. PLoS ONE 8:e78935, 2013
201. Seltzer MJ, Bennett BD, Joshi AD, Gao P, Thomas AG, Ferraris DV, et al: Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res 70:8981-8987, 2010
202. Semenza GL: HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest 123:3664-3671, 2013
203. Semenza GL: HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20:51-56, 2010
204. Semenza GL: Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE 2007:cm8, 2007
205. Shao R, Zhang FP, Tian F, Anders Friberg P, Wang X, Sjöland H, et al: Increase of SUMO-1 expression in response to hypoxia: direct interaction with HIF-1alpha in adult mouse brain and heart in vivo. FEBS Lett 569:293-300, 2004
206. Sharma V, Dixit D, Koul N, Mehta VS, Sen E: Ras regulates interleukin-1b-induced HIF-1a transcriptional activity in glioblastoma. J Mol Med (Berl) 89:123-136, 2011
207. Shin DH, Chun YS, Lee DS, Huang LE, Park JW: Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIHmediated repression of hypoxia-inducible factor-1. Blood 111:3131-3136, 2008
208. Solaini G, Sgarbi G, Baracca A: Oxidative phosphorylation in cancer cells. Biochim Biophys Acta 1807:534-542, 2011
209. Søndergaard KL, Hilton DA, Penney M, Ollerenshaw M, Demaine AG: Expression of hypoxia-inducible factor 1alpha in tumours of patients with glioblastoma. Neuropathol Appl Neurobiol 28:210-217, 2002
210. Song LP, Zhang J, Wu SF, Huang Y, Zhao Q, Cao JP, et al: Hypoxia-inducible factor-1alpha-induced differentiation of myeloid leukemic cells is its transcriptional activity independent. Oncogene 27:519-527, 2008
211. Sonoda Y, Murakami Y, Tominaga T, Kayama T, Yoshimoto T, Sekiya T: Deletion mapping of chromosome 10 in human glioma. Jpn J Cancer Res 87:363-367, 1996
212. Span PN, Bussink J, Manders P, Beex LV, Sweep CG: Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome. Br J Cancer 89:271-276, 2003
213. Stancheva G, Goranova T, Laleva M, Kamenova M, Mitkova A, Velinov N, et al: IDH1/IDH2 but not TP53 mutations predict prognosis in Bulgarian glioblastoma patients. Biomed Res Int 2014:654727, 2014
214. Stieber VW, Mehta MP: Advances in radiation therapy for brain tumors. Neurol Clin 25:1005-1033, ix, 2007
215. Stupp R, van den Bent MJ, Hegi ME: Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep 5:198-206, 2005
216. Stupp R, Weber DC: The role of radio- and chemotherapy in glioblastoma. Onkologie 28:315-317, 2005
217. Subbarayan PR, Wang PG, Lampidis TJ, Ardalan B, Braunschweiger P: Differential expression of Glut 1 mRNA and protein levels correlates with increased sensitivity to the glycoconjugated nitric oxide donor (2-glu-SNAP) in different tumor cell types. J Chemother 20:106-111, 2008
218. Sullivan LB, Martinez-Garcia E, Nguyen H, Mullen AR, Dufour E, Sudarshan S, et al: The proto-oncometabolite fumarate binds glutathione to amplify ROS-dependent signaling. Mol Cell 51:236-248, 2013
219. Sun W, Jelkmann W, Depping R: Prolyl-4-hydroxylase 2 enhances hypoxia-induced glioblastoma cell death by regulating the gene expression of hypoxia-inducible factor-a. Cell Death Dis 5:e1322, 2014
220. Sundfør K, Lyng H, Rofstad EK: Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix. Br J Cancer 78:822-827, 1998
221. Sutendra G, Michelakis ED: Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology. Front Oncol 3:38, 2013
222. Tan C, de Noronha RG, Roecker AJ, Pyrzynska B, Khwaja F, Zhang Z, et al: Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res 65:605-612, 2005
223. Theodoropoulos VE, Lazaris ACh, Sofras F, Gerzelis I, Tsoukala V, Ghikonti I, et al: Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol 46:200-208, 2004
224. Vajkoczy P, Menger MD: Vascular microenvironment in gliomas. Cancer Treat Res 117:249-262, 2004
225. Van Meir EG: Cytokines and tumors of the central nervous system. Glia 15:264-288, 1995
226. Velpula KK, Bhasin A, Asuthkar S, Tsung AJ: Combined targeting of PDK1 and EGFR triggers regression of glioblastoma by reversing the Warburg effect. Cancer Res 73:7277-7289, 2013
227. Verma RP, Hansch C: Camptothecins: a SAR/QSAR study. Chem Rev 109:213-235, 2009
228. Wachsberger PR, Lawrence YR, Liu Y, Rice B, Feo N, Leiby B, et al: Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma. J Cancer Res Clin Oncol 140:573-582, 2014
229. Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfør K, Rofstad EK, et al: High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res 60:916-921, 2000
230. Wan X, Shen N, Mendoza A, Khanna C, Helman LJ: CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/ VEGF signaling. Neoplasia 8:394-401, 2006
231. Wang E, Zhang C, Polavaram N, Liu F, Wu G, Schroeder MA, et al: The role of factor inhibiting HIF (FIH-1) in inhibiting HIF-1 transcriptional activity in glioblastoma multiforme. PLoS ONE 9:e86102, 2014
232. Wang F, Osawa T, Tsuchida R, Yuasa Y, Shibuya M: Downregulation of receptor for activated C-kinase 1 (RACK1) suppresses tumor growth by inhibiting tumor cell proliferation and tumor-associated angiogenesis. Cancer Sci 102:2007-2013, 2011
233. Wang GL, Jiang BH, Rue EA, Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 92:5510-5514, 1995
234. Wang Q, Hu DF, Rui Y, Jiang AB, Liu ZL, Huang LN: Prognosis value of HIF-1a expression in patients with non-small cell lung cancer. Gene 541:69-74, 2014
235. Warburg O: On the origin of cancer cells. Science 123:309-314, 1956
236. Welsh JW, Mahadevan D, Ellsworth R, Cooke L, Bearss D, Stea B: The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Radiat Oncol 4:69, 2009
237. Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, Powis G: The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther 2:235-243, 2003
238. Wicks RT, Azadi J, Mangraviti A, Zhang I, Hwang L, Joshi A, et al: Local delivery of cancer-cell glycolytic inhibitors in highgrade glioma. Neuro Oncol [epub ahead of print], 2014
239. Wilson RE, Keng PC, Sutherland RM: Drug resistance in Chinese hamster ovary cells during recovery from severe hypoxia. J Natl Cancer Inst 81:1235-1240, 1989
240. Wolf A, Agnihotri S, Guha A: Targeting metabolic remodeling in glioblastoma multiforme. Oncotarget 1:552-562, 2010
241. Wolf A, Agnihotri S, Micallef J, Mukherjee J, Sabha N, Cairns R, et al: Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med 208:313-326, 2011
242. Wolf A, Agnihotri S, Munoz D, Guha A: Developmental profile and regulation of the glycolytic enzyme hexokinase 2 in normal brain and glioblastoma multiforme. Neurobiol Dis 44:84-91, 2011
243. Xia Y, Choi HK, Lee K: Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur J Med Chem 49:24-40, 2012
244. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, et al: Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 65:613-621, 2005
245. Yang W, Wang L, Roehn G, Pearlstein RD, Ali-Osman F, Pan H, et al: Small ubiquitin-like modifier 1-3 conjugation [corrected] is activated in human astrocytic brain tumors and is required for glioblastoma cell survival. Cancer Sci 104:70-77, 2013 (Erratum in Cancer Sci 104:70-77, 2013)
246. Yeo EJ, Ryu JH, Cho YS, Chun YS, Huang LE, Kim MS, et al: Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1. Blood 107:916-923, 2006
247. Yin S, Kaluz S, Devi NS, Jabbar AA, de Noronha RG, Mun J, et al: Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1a interaction with cofactors p300/CBP. Clin Cancer Res 18:6623-6633, 2012
248. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL: Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88:2606-2618, 2000
249. Zhang W, Petrovic JM, Callaghan D, Jones A, Cui H, Howlett C, et al: Evidence that hypoxia-inducible factor-1 (HIF-1) mediates transcriptional activation of interleukin-1beta (IL-1beta) in astrocyte cultures. J Neuroimmunol 174:63-73, 2006
250. Zhang Y, Liu Q, Wang F, Ling EA, Liu S, Wang L, et al: Melatonin antagonizes hypoxia-mediated glioblastoma cell migration and invasion via inhibition of HIF-1a. J Pineal Res 55:121-130, 2013
251. Zhao S, Liu H, Liu Y, Wu J, Wang C, Hou X, et al: miR-143 inhibits glycolysis and depletes stemness of glioblastoma stemlike cells. Cancer Lett 333:253-260, 2013
252. Zhao YS, Zhu TZ, Chen YW, Yao YQ, Wu CM, Wei ZQ, et al: B-elemene inhibits Hsp90/Raf-1 molecular complex inducing apoptosis of glioblastoma cells. J Neurooncol 107:307-314, 2012
253. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59:5830-5835, 1999
254. Zhou Z, Liu F, Zhang ZS, Shu F, Zheng Y, Fu L, et al: Human rhomboid family-1 suppresses oxygen-independent degradation of hypoxia-inducible factor-1a in breast cancer. Cancer Res 74:2719-2730, 2014
255. Zhu H, Woolfenden S, Bronson RT, Jaffer ZM, Barluenga S, Winssinger N, et al: The novel Hsp90 inhibitor NXD30001 induces tumor regression in a genetically engineered mouse model of glioblastoma multiforme. Mol Cancer Ther 9:2618-2626, 2010
256. Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, et al: Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14:391-396, 2000
257. Zwicker F, Kirsner A, Peschke P, Roeder F, Debus J, Huber PE, et al: Dichloroacetate induces tumor-specific radiosensitivity in vitro but attenuates radiation-induced tumor growth delay in vivo. Strahlenther Onkol 189:684-692, 2013